Ardelyx Wins Multiple Awards at PM360 Trailblazer Awards

WALTHAM, Mass., Sept. 30, 2026 /CourierPR/ -- Ardelyx, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, has earned multiple honors at the 2026 PM360 Trailblazer Awards, recognizing the company, its leadership, and the work of teams across the organization.

The company received the Life Sciences Manufacturer CEO of the Year award for Mike Raab, who has led Ardelyx from an early-stage biotechnology company into a commercial, multi-product biopharmaceutical organization since becoming CEO in 2009. Under Raab's guidance, Ardelyx has advanced two first-in-class medicines and significantly grown its organizational structure, with plans to expand its development pipeline.

Additionally, Ardelyx's podcast initiative, Gut Matters: Discoveries and Innovations, was named the Gold Winner in the Podcast Initiative category. Hosted by Johannah Ruddy, senior director of patient advocacy at Ardelyx, and gastroenterologist Andrea Shin, MD, Gut Matters brings together patients, caregivers, advocacy leaders, and medical experts for credible and informative conversations about IBS-C and other disorders of gut-brain interaction. The podcast's recent Fierce Pharma Marketing Award win further solidified its position as a leader in the industry.

The IBSRELA Marketing Team was awarded the Silver Marketing Team of the Year award, recognized for its strategic, collaborative, and patient-focused approach to marketing. The team's efforts have been instrumental in advancing Ardelyx's products and elevating patient perspectives.

These honors recognize Ardelyx's growth as a company and the contributions of its leaders and employees to advancing innovation, supporting patients, and developing new approaches to life sciences education and engagement. The PM360 Trailblazer Awards, which were announced during the annual Trailblazer Awards Gala held September 29, 2026, in New York City, recognize outstanding companies, leaders, marketers, teams, and initiatives in the life sciences industry.

Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The company has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx's pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. The company works with partners to develop and commercialize its products outside of the United States.